Wired News – Illumina Won $26.7 Million in Patent Suit Against Ariosa Diagnostics

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free research report on Illumina, Inc. (NASDAQ: ILMN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ILMN as the Company’s latest news hit the wire. On January 26, 2018, the Company announced that it has won approximately $26.7 million in a patent infringement lawsuit against Ariosa Diagnostics, Inc., a subsidiary of Roche Holdings AG, related to Illumina’s non-invasive prenatal testing technology (NIPT). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Illumina most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ILMN

In November 2017, the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in Illumina’s favor in the lawsuit filed against Ariosa.

The Jury Rejected Ariosa’s Counterclaims of a Breach of Contract

The jury in the US District Court for the Northern District of California found that both Ariosa’s previous and current version of the Harmony NIPT infringe US Patent 8,318,430 and US Patent 7,955,794. The jury rejected counterclaims by Ariosa that Illumina had breached a supply agreement between the companies by bringing the lawsuit. Illumina intends to seek injunctive relief for ongoing infringement by Ariosa’s continuing sale of its Harmony test.

Lawsuits Filed Against Ariosa in 2014 and 2015

In April 2014, Illumina filed a lawsuit against Ariosa, based on the latter’s infringement of US Patent No. 7,955,794, entitled “Multiplex Nucleic Acid Reactions.” The suit targeted Ariosa’s Harmony NIPT, including its use of digital analysis of selected regions (DANSR) that, among other things, enabled simultaneous quantification of hundreds of DNA loci.

In May 2015, the Company filed another lawsuit after Roche had acquired Ariosa and converted its NIPT to run on a microarray. Illumina claimed that the microarray version of the test also infringed on its ‘7,955,794-patent because it used the same technique as the sequencing-based test. Ariosa also infringed 8,318,430-patent entitled “Methods of Fetal Abnormality Detection”.

Illumina Won Infringement Suit Against Premaitha

In November 2017, Patents Court in the United Kingdom also issued a judgment in Illumina’s favor in the patent infringement suit filed against Premaitha Health PLC. The Court found that Premaitha’s IONA test infringed EP 1 981 995, EP 2 385 143, EP 2 183 693 and EP 2 514 842, which are generally directed to the use of sequencing in NIPT. The Court also found that the gender testing component in Premaitha’s IONA test infringe EP 0 994 963. These patents are licensed by Illumina or its wholly owned subsidiary Verinata Health, Inc.

About Illumina, Inc.

Founded in 1998 and headquartered in San Diego, California, Illumina is a global leader in genomics, an industry at the intersection of biology and technology, serving customers in the research, clinical and applied markets. The Company offers the verifi® NIPT in its CLIA-certified, CAP-accredited clinical services laboratory, to detect chromosome abnormalities and aberrations with improved resolution for consistent, and dependable results.

About Ariosa Diagnostics, Inc.

Established in 2010, Ariosa Diagnostics, maker of the HarmonyTM Prenatal Test, is a molecular diagnostics company committed to providing non-invasive, highly accurate, and affordable prenatal tests for all pregnant women in an effort to promote and improve maternal and fetal health. Headquartered in San Jose, California, the Company was acquired by Roche in 2014.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, Illumina’s stock fell 1.25%, ending the trading session at $241.78.

Volume traded for the day: 779.51 thousand shares.

Stock performance in the last month – up 12.22%; previous three-month period – up 16.07%; past twelve-month period – up 50.18%; and year-to-date – up 10.66%

After yesterday’s close, Illumina’s market cap was at $35.09 billion.

Price to Earnings (P/E) ratio was at 45.58.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487328